View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
August 24, 2021updated 23 Aug 2021 5:14pm

Low accrual rate terminates the most Covid-19 trials

Low accrual rate accounts for 25.0% of all Covid-19 trial terminations to date, more than any other cause of termination.

By GlobalData Healthcare

New variant strains of Covid-19, such as the Delta and now Lambda variants, continue to raise the number of cases around the world. Data captured from GlobalData’s Pharma Intelligence Centre since the beginning of the pandemic show low accrual rate was the top reason for trial termination within clinical trials for Covid-19.

In total, there have been more than 150 trial terminations for Covid-19 trials. The top reason for trial termination was low accrual rate, followed by lack of efficacy and production discontinuation. Low accrual rate accounted for 25.0% of all Covid-19 trial terminations, with lack of efficacy at 14.5%.

A further breakdown can be seen in Figure 1. When looking at trial terminations by phase, the most were seen in Phase II (42.4%) and then Phase III (39.7%), corresponding with the most total trials. Low accrual rate accounted for 52.6% of Phase II trials, followed by 26.3% of Phase III trials. Lastly, North America currently has the most terminated trials by region due to low accrual rate. These numbers may be due to the increase in the number of vaccinations being administered, which lowers the number of patients available.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU